Nevertheless, in all these studies so far, response rates and duration of response seem to be limited in pancreatic cancer, possibly due to emergence of secondary resistance-mediating oncogenic variants or due to clonal selection of pre-existing alternative oncogenic driver KRAS alterations [29]. The gene discussed is KRAS; the disease is pancreatic neoplasm.